stockrow
Friday 6 November 2026
Export DXCM’s income statement to Excel — free account
DexCom, Inc.
DXCM Healthcare Medical Devices
DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024.
- Revenue
- +11.2%
- EPS
- 0.00%
- Free cash flow
- −52.9%
- Total debt
- +0.31%
Quarter to September 2026, against a year earlier
80.00
4.46
−5.28%
Follow DXCM
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
33.32 | 26.00 | 26.17 | 30.87 |
+8 more quarters Free account |
P/S ratio |
6.33 | 5.18 | 5.02 | 5.56 | |
P/FCF ratio |
29.44 | 18.32 | 16.92 | 24.04 | |
P/Operating CF |
99.30 | 95.62 | 46.01 | 88.09 | |
P/B ratio |
12.75 | 9.82 | 8.18 | 9.43 | |
Price to Tangible BV |
13.35 | 10.31 | 8.43 | 9.77 | |
EV/Sales |
6.37 | 5.19 | 4.94 | 5.56 | |
EV/EBITDA |
21.70 | 18.39 | 18.40 | 22.27 | |
EV/Operating CF |
23.00 | 14.76 | 13.34 | 17.99 | |
EV/FCF |
29.62 | 18.37 | 16.64 | 24.06 | |
Quick Ratio |
1.33 | 1.36 | 1.58 | 1.50 | |
Current Ratio |
1.74 | 1.73 | 1.95 | 1.88 | |
Net Debt/EBITDA |
(1.43) | (1.82) | (3.64) | (1.95) | |
Debt/Assets |
19.93% | 19.25% | 18.72% | 19.57% | |
Debt/Equity |
0.49 | 0.47 | 0.42 | 0.45 | |
Asset Turnover |
0.74 | 0.72 | 0.72 | 0.73 | |
Operating CF/Net income |
1.18 | 1.08 | 2.63 | 1.10 | |
Capex/Depreciation |
(0.71) | (1.24) | (1.14) | (1.56) | |
Research and Development Expense of Revenue |
12.02% | 11.69% | 12.19% | 11.77% | |
Selling, General and Administrative Expense of Revenue |
27.94% | 27.42% | 29.34% | 25.52% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.01 | 0.02 | |
Share Based Compensation of Revenue |
2.74% | 2.98% | 3.63% | 2.78% | |
Graham Net Nets |
0.01 | 0.01 | 0.03 | 0.02 | |
Graham Number |
19.86 | 19.99 | 20.36 | 18.45 | |
Earnings Yield |
3.00% | 3.85% | 3.82% | 3.24% | |
Free Cash Flow Yield |
3.40% | 5.46% | 5.91% | 4.16% | |
Revenue per Share |
3.59 | 3.42 | 3.10 | 3.23 | |
Operating CF per Share |
0.87 | 0.70 | 1.36 | 0.75 | |
Capex per Share |
(0.14) | (0.22) | (0.20) | (0.26) | |
Free Cash Flow per Share |
0.73 | 0.48 | 1.17 | 0.49 | |
Cash per Share |
4.85 | 5.09 | 6.27 | 5.12 | |
Shareholders Equity per Share |
6.77 | 6.86 | 7.68 | 7.04 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.77 | 6.86 | 7.68 | 7.04 | |
Free Cash Flow |
272.70 | 184.50 | 449.00 | 192.10 | |
Working Capital |
1,663.40 | 1,728.90 | 2,107.90 | 1,890.80 | |
Capital Expenditures |
(52.90) | (84.70) | (76.60) | (101.90) | |
Net Current Asset Value |
212.60 | 252.70 | 655.30 | 439.40 | |
EV/EBIT |
26.58 | 22.66 | 23.01 | 28.42 | |
Capex to Sales |
0.04 | 0.06 | 0.06 | 0.08 | |
Price to Operating Income |
26.42 | 22.60 | 23.40 | 28.40 | |
| Other line items | |||||
Average Receivables |
1,147.90 | 1,303.25 | 1,121.90 | 1,110.90 | |
Average Payables |
1,999.00 | 2,067.65 | 1,882.25 | 1,764.55 | |
Average Inventory |
687.40 | 648.55 | 615.90 | 585.85 | |
Average Assets |
6,869.40 | 6,891.15 | 6,692.50 | 6,412.20 | |
Average Common Equity |
2,630.75 | 2,597.25 | 2,611.75 | 2,424.30 |
Columns are period end dates · fundamentals updated 5 Nov 2026